Raul Cordoba, Attending Physician, Department of Hematology at MD Anderson Cancer Center Madrid, Chief Strategy Officer at Spanish Society of Hematology and Hemotherapy, shared a post on X about a recent article by Umberto Vitolo et al, published in Lancet Haematology:
“Just Released
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.”
Title: Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
Authors: Umberto Vitolo, Juan Miguel Bergua Burgues, Johannes Duell, Michal Kwiatek, David Belada, Wojciech Jurczak, Marie Maerevoet, David Sibon, Richard Greil, Takahiro Kumode, Javier López-Jimenez, Caressa Meert, Juan-Manuel Sancho Cia, Catherine Thieblemont, Sergio Ortegon Alcaide, Won Seog Kim, Raul Cordoba, Monica Wielgos-Bonvallet, Tony Jiang, Yanli Wang, Stephanie McGoldrick, Evelyn Guo, Franck Morschhauser, F. J. Sherida H. Woei-A-Jin
Read the Full Article on Lancet Haematology
More posts featuring Raul Cordoba.